Establishment Labs Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that CEO Juan José Chacón-Quirós will speak at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 4:30 PM ET. The conference will highlight the company's focus on women's health, particularly in breast aesthetics and reconstruction markets. A live webcast will be available for interested parties, with an archived version following the event. Establishment Labs is recognized for its Motiva Implants® and other innovative technologies, which are available in over 80 countries.
- CEO participation at a significant healthcare conference could enhance visibility and investor interest.
- Establishment Labs is expanding its presence in over 80 countries, which demonstrates strong international demand.
- None.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós will participate in the 39th Annual J.P. Morgan Healthcare Conference, which is being held January 11-14, 2021. Mr. Chacón-Quirós is scheduled to speak to conference attendees at 4:30 pm ET on Thursday, January 14, 2021.
A live webcast of the presentation will be available to all interested parties on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following the completion of the event.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at www.establishmentlabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005229/en/
FAQ
When is Juan José Chacón-Quirós speaking at the J.P. Morgan Healthcare Conference?
What is the focus of Establishment Labs' business?
Where can I watch the webcast of the conference presentation?
What products does Establishment Labs offer?
